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Significant but lesser changes in losartan utilization were seen in 
Austria and Belgium. There was no change in losartan utilization 
patterns in Scotland or Spain. Losartan typically generic at low prices, 
leading to appreciable increases in prescribing efficiency in NHS Bury, 
Sweden, Austria, and Belgium. There were some savings in Scotland 
with generic losartan.
Conclusion: Multiple demand-side measures appreciably enhanced 
ARB prescribing efficiency. This mirrors previous findings that mul-
tiple measures are need to change prescribing habits. No significant 
increase in losartan utilization following generics where countries 
have not instigated specific measures suggests authorities cannot rely 
on a “spillover” effect between classes to change physician prescrib-
ing habits. This is the case even with multiple demand-side activities 
encouraging preferential prescribing of generics in related classes. 
This may be exacerbated on this occasion by a more complex mes-
sage; for example, away from ACEIs first line versus ARBs to ACEIs 
+ low cost ARBs first line.
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Introduction: The availability of generic venlafaxine is an opportu-
nity for health authorities to save resources given the prevalence of 
depression. However, depression can be complex to treat, with physi-
cians reluctant to change prescriptions if patients are responding to a 
particular antidepressant. Consequently, there is a need to assess: (1) 
changes in the utilization pattern of venlafaxine versus other newer 
antidepressants before and after the availability of generic venla-
faxine and before and after prescribing restrictions were introduced 
for duloxetine in Sweden limiting prescribing to refractory patients; 
(2) utilization of generic versus originator venlafaxine; and (3) price 
reductions for generic venlafaxine and subsequent expenditure on 
newer antidepressants over time, to guide future reforms.
Patients (or Materials) and Methods: Interrupted time series ana-
lyzing the changes in aggregated dispensed prescriptions (DDDs 
[defined daily doses]) of patients dispensed at least 1 of the newer 
antidepressant from January 2007 to August 2011. This included 
time before the availability of generic venlafaxine to 19 months after 
the availability of generic venlafaxine but before prescribing restric-
tions introduced for duloxetine and to 13 months after prescribing 
restrictions were introduced for duloxetine. Expenditure measured, 
which included price reductions for generic venlafaxine over time.
Results: There was no appreciable change in the utilization of venla-
faxine after generic availability but before prescribing restrictions for 
duloxetine with no appreciable demand-side activities by the regions 
(counties) to preferentially encourage its prescribing. However, the 
utilization of venlafaxine significantly increased after the introduction 
of prescribing restrictions for duloxetine, although no appreciable 
change in the utilization of duloxetine. Principally, generic venlafax-
ine was prescribed and dispensed versus the originator once available. 
There was an appreciable fall in expenditure for venlafaxine follow-
ing generics that lead to a fall in expenditure for newer antidepres-
sants in Sweden after generic venlafaxine became available.
Conclusion: No apparent concerns with generic venlafaxine among 
physicians versus the originator. Multiple demand-side measures 
are needed to change physician prescribing habits. Authorities can-
not rely on a “spillover” effect between classes to change physician 
prescribing habits. The limited influence of prescribing restrictions 
on the subsequent utilization of duloxetine reflects the complexity 
of the disease area versus treating acid-related stomach disorders, 
hypercholesterolemia, or hypertension. However, the influence of the 
prescribing restrictions for duloxetine resulting in increased utiliza-
tion of venlafaxine is encouraging.
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Introduction: White blood cell (WBC) monitoring is mandatory in 
several countries among schizophrenic patients treated by clozap-
ine, because of the risk of drug-induced agranulocytosis. Our aim is 
to compare the cost-effectiveness of 4 WBC- monitoring strategies 
(United Kingdom, United States, Switzerland, and an weekly short-
run monitoring) to the absence of monitoring.
Patients (or Materials) and Methods: We built a semi-Markovian 
model to conduct a cost-utility analysis from a health care perspective 
with a 3-year time horizon, assuming a probability of agranulocytosis 
of 0.7% at 3 years. Clinical and resources used parameters were 
based on national clozapine patients’ registries, cohorts, and Swiss 
pharmacovigilance data; health-related quality of life and mortality 
estimates were derived from literature reviews. Model uncertainty 
was was assessed with 1-way and probabilistic sensitivity analyses.
Results: In our model, compared with the absence of monitoring, all 
4 monitoring strategies increased the quality-adjusted survival simi-
larly by < 1 day, with 5000 patients to monitor to avoid 1 death. The 
incremental cost-effectiveness ratio (ICER) was at least $1,000,000 
per QALY gained for all 4 strategies compared with no monitoring. 
It was higher in strategies with higher frequency and longer moni-
toring duration. The results remain robust in the 1-way sensibility 
analyses and the probabilistic sensitivity analysis, indicating that the 
absence of monitoring strategy had the highest probability of cost-
effectiveness for willingness-to-pay under $1,000,000.
Conclusion: Current WBC monitoring based on current national 
detection guidelines do not appear to be cost-effective. New guide-
lines are needed to improve WBC monitoring in schizophrenic 
patients receiving clozapine.
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Introduction: The Scottish Medicines Consortium (SMC) provides 
advice about clinical- and cost-effectiveness of newly licensed medi-
cines to the National Health Service (NHS) in Scotland. Since 2005, 
SMC has also provided early intelligence on medicines in develop-
mentthrough “Forward Look” (FL) reports. An investigation was 
undertaken to examine the completeness of FL and its usefulness to 
NHS Boards.
Patients (or Materials) and Methods: (1) Significant medicines 
(with the potential for net budget impact exceeding UK£500,000 
per annum at year 5 and/or significant service implications or orphan 
status) in FL reports (April 2006-October 2008) were compared 
with SMC advice. The actual launch date was compared with the 
FL predicted date to determine if the medicine was launched within 
expected time frames. (2) SMC advice (April 2006 - March 2010) 
for all medicines was compared with FL reports. For medicines that 
were not included in FL reports but accepted by SMC, those predicted 
by the manufacturer to have a budget impact ≥ UK£500,000 were 
identified. (3) Interviews were held with NHS Directors of Finance 
and Directors of Pharmacy to explore how FL reports were used at 
NHS Board level.
Results: (1) Of 116 significant FL medicines, 81 (70%) medicines 
were reviewed by SMC; only 4 of the medicines not reviewed by SMC 
had been launched in the United Kingdom. A total of 52 (45%) of 
the 116 medicines were launched within time frames predicted by FL. 
Of the remaining 64 medicines, 31 were launched out with expected 
time frames; 31 were not launched in the UK; and, for 2 medicines, 
data were unavailable. (2) Of 215 medicines that were reviewed by 
SMC (April 2006 to March 2010), 123 (57%) medicines had been 
included in FL reports. Of the 92 (43%) medicines that were not 
included in FL reports, 53 were accepted for use or restricted use by 
SMC, including 7 medicines that were predicted by the pharmaceuti-
cal company to have a net budget impact ≥ £500,000 at year 5. (3) 
The qualitative study demonstrated that although NHS Boards did 
not view FL as completely accurate, it was a useful source of intel-
ligence on medicines in the pipeline and an important starting point 
for local clinical engagement.
Conclusion: Most significant medicines in FL reports were subse-
quently launched and reviewed by SMC. As expected, it was challeng-
ing to accurately predict the launch date of medicines in development, 
with many launched out with expected timef rames and some not 
launched at all. Despite the limitations, FL was considered a useful 
source of intelligence on medicines in the pipeline.
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Introduction: Self-medication increases the risk of overuse and 
innappropriate use of antibiotics with implications for increasing 
adverse events, treatment costs for individuals, and selection of resist-
ant bacteria in whole population.The aim of the present study was to 
analyze the amount and structure of antibiotics issued on prescription 
and bought without prescription and to investigate the influence of 
the price on the antibiotics consumption.
Patients (or Materials) and Methods: The investigation was carried 
out in the Novi Sad (323,708 inhabitants), Serbia, over a 3-month 
period, from January 1 to March 31, 2008. The data on the number 
of packages, size of packages, and retail price of antibiotics (ATC 
group J01) were obtained from all state-owned and private pharma-
cies in Novi Sad. The data are presented as number of DDD/1000 
inhabitants/d. Costs/DDD was also calculated. The DU90% meth-
odology was used.
Results: Seventy-six percent of antibiotics were issued by prescrip-
tion, while 23.94% were bought without prescription in Novi Sad. 
Penicillins, cephalosporins, and macrolides were the most prescribed 
antibiotic classes. By contrast, penicillins, tetracyclines, and cepha-
losporins were the most frequently bought antibiotics. The average 
price per DDD within the DU90% segment was 0.90 Euro/DDD 
for antibiotics issued by prescription, while for antibiotics bought 
without prescription, it was only 0.65 Euro/DDD, indicating that 
less expensive drugs were bought without prescription. The cheap-
est drug/DDD was doxycyclin (0.21 Euro/DDD) and it occupied the 
first position among antibiotics bought without prescription, while 
it was on the third place among antibiotics issued by prescription. 
The most expensive drugs/DDD were azithromycin (1.52 Euro/DDD) 
and ciprofloxacine (1.52 Euro/DDD). They occupied the high fourth 
and the eighth place among antibiotics issued by prescription. Among 
antibiotics bought without prescription, these expensive drugs occu-
pied the seventh and the eighth places.
Conclusion: The results of our study clearly show that a significant 
amount of antibiotics were dispensed in the private pharmacies with-
out prescription in Novi Sad, Serbia. The financial aspects strongly 
influence the antibiotics consumption without prescription. The influ-
ence of administrative measures, introduced recently on the usage of 
antibiotics, will be follow. This work was supported by the Ministry 
of Science and Technological Development, Republic of Serbia, pro-
ject No. 41012.
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Introduction: In resource-poor countries, access to essential medicines, 
and suboptimal prescribing and use of medicines, are major public health 
